MG MED Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
2,086
2,555
13,930
20,088
36,830
Total Accounts Receivable
631
815
761
721
912
Inventories
177
226
424
438
517
Other Current Assets
16
17
206
31
42
Total Current Assets
2,909
3,614
15,322
21,277
38,301
Net Property, Plant & Equipment
3,294
3,412
3,387
3,593
5,463
Total Investments and Advances
1
-
-
-
7,388
Long-Term Note Receivable
-
-
1,265
1,149
432
Intangible Assets
411
361
321
267
134
Other Assets
197
83
1,796
3,149
5,517
Total Assets
7,118
7,795
22,326
29,697
57,235
ST Debt & Current Portion LT Debt
5,264
-
-
-
-
Accounts Payable
226
278
304
276
263
Income Tax Payable
1
41
68
-
5
Other Current Liabilities
213
204
248
368
1,192
Total Current Liabilities
5,705
523
619
645
1,461
Long-Term Debt
-
-
-
-
21,025
Deferred Taxes
246
235
88
262
-
Total Liabilities
5,764
613
767
645
22,485
Common Equity (Total)
1,354
7,182
21,559
29,052
34,749
Total Shareholders' Equity
1,354
7,182
21,559
29,052
34,749
Total Equity
1,354
7,182
21,559
29,052
34,749
Liabilities & Shareholders' Equity
7,118
7,795
22,326
29,697
57,235

About MG MED

View Profile
Address
Unit 1003, Elysia Building
Seoul SL 08511
Korea, Republic Of
Employees -
Website http://www.cancerrop.com
Updated 09/14/2018
Cancer Rop Co., Ltd. engages in the development of molecular diagnostic products. It operates through Molecular Diagnostics and Bio-Reagents Business divisions. The molecular diagnostic business division provides deoxyribonucleic acid (DNA) chips and polymerase chain reaction(PCR) kits.